HeartVar demonstrates that an LLM constrained by a domain-specific prompt and grounded in structured evidence can produce variant interpretations of first-pass quality for a cardiovascular disease cohort; however, it is not intended to replace manual assessment by a qualified variant curator.
Abstract
Manual clinical DNA variant classification is the bottleneck of every clinical and research rare disease workflow. The process typically requires a curator to assemble evidence from numerous databases, weigh 28 criteria, reconcile competing evidence, and produce a defensible case for the final classification. Additionally, the framework used to assess variants is not static and successive addenda have revised individual criteria. The most complete and current evidence aggregators available are commercial platforms, which can limit researcher access. We present HeartVar, an open-source web tool that automates the evidence-gathering and interpretation steps of variant classification associated with cardiovascular disease. Given a gene, a variant, and clinical context, HeartVar queries 20 public databases in parallel and assigns ACMG/AMP criteria through a hybrid rule-based/large language model (LLM) approach. Criteria that can be resolved from structured data are computed programmatically, and only those requiring interpretation of unstructured evidence are passed to the LLM. HeartVar returns a classification, point score, per-criterion breakdown, clinical-narrative summary, and database annotations. Benchmarking of 106 expert-curated ClinGen variants showed HeartVar outperformed other curation tools, assigning the correct ACMG tier in 72% of cases. HeartVar demonstrates that an LLM constrained by a domain-specific prompt and grounded in structured evidence can produce variant interpretations of first-pass quality for a cardiovascular disease cohort; however, it is not intended to replace manual assessment by a qualified variant curator. The tool is freely available to use and hosted at www.heartvar.victorchang.edu.au.
Automated platforms that classify sequence variants under the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) framework are increasingly used in rare-disease genomics, yet methodology for characterizing their performance at an early organizational stage is underdeveloped...
Vladimir Mitev· Frontiers in Genetics· 0 citations
LLMs are suitable for information extraction of medications from clinical notes for use in research databases, however, for a clinical setting where the treatment of patients would be dependent on LLM performance, the current state-of-the-art open weight models are not accurate enough.
T. Spreuer, A. Günther, R. Majeed· Studies in Health Technology...· 0 citations
AI/ML models show promise for predicting CV adverse events in patients with cancer; however, clinical applicability is constrained by insufficient preprocessing transparency, limited external validation, and inadequate calibration reporting.
Li-Wei Wu, Minh-Anh Le-Dang, B. Okoye et al.· Expert review of pharmacoeco...· 0 citations
Results provide an indication that an integrated, interpretable, and data-efficient learning system has the potential to support screening and risk of cardiovascular disease in the early stages of care and inform preventive care in a real healthcare environment.
Abrar Rakin, Md. Istiak Ahamed, Farhan Hassin et al.· E3S Web of Conferences· 0 citations
An open-source, human-verified workflow using large language models can accelerate electronic health record abstraction while improving accuracy and supports broader adoption of transparent artificial intelligence methods in clinical research.
Carl Jannes Neuse, Malte Janssen, S. Ibing et al.· BMC Medical Informatics and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.